Kymera Therapeutics (NASDAQ:KYMR – Get Rating) had its price objective increased by Wells Fargo & Company from $40.00 to $42.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 73.27% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Credit Suisse Group lowered shares of Kymera Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $47.00 to $32.00 in a report on Monday, December 5th. Raymond James began coverage on Kymera Therapeutics in a report on Tuesday, November 8th. They issued a “market perform” rating on the stock. B. Riley increased their target price on Kymera Therapeutics from $35.00 to $37.00 in a research note on Thursday, December 15th. SVB Leerink lifted their price target on Kymera Therapeutics from $26.00 to $31.00 and gave the stock a “market perform” rating in a research report on Thursday, December 15th. Finally, Piper Sandler increased their price objective on shares of Kymera Therapeutics from $43.00 to $58.00 in a research report on Wednesday, December 14th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics has an average rating of “Hold” and an average target price of $41.89.
Kymera Therapeutics Price Performance
KYMR stock traded down $0.72 during trading on Tuesday, reaching $24.24. The company had a trading volume of 8,118 shares, compared to its average volume of 1,048,638. Kymera Therapeutics has a 52 week low of $13.15 and a 52 week high of $66.45. The business has a 50 day moving average of $28.00 and a 200 day moving average of $25.92. The company has a market cap of $1.33 billion, a P/E ratio of -8.24 and a beta of 1.45.
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). The business had revenue of $9.55 million for the quarter, compared to the consensus estimate of $16.42 million. Kymera Therapeutics had a negative net margin of 334.72% and a negative return on equity of 34.20%. Research analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.
Insider Transactions at Kymera Therapeutics
In related news, Director Bruce Booth sold 378,966 shares of the company’s stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $31.37, for a total transaction of $11,888,163.42. Following the completion of the sale, the director now owns 918,528 shares in the company, valued at $28,814,223.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 94,239 shares of the firm’s stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $30.23, for a total transaction of $2,848,844.97. Following the sale, the insider now owns 5,597,638 shares in the company, valued at approximately $169,216,596.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bruce Booth sold 378,966 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, December 14th. The shares were sold at an average price of $31.37, for a total transaction of $11,888,163.42. Following the transaction, the director now directly owns 918,528 shares in the company, valued at approximately $28,814,223.36. The disclosure for this sale can be found here. Insiders have sold a total of 1,272,289 shares of company stock worth $39,147,301 in the last ninety days. Insiders own 17.01% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Teachers Retirement System of The State of Kentucky bought a new stake in Kymera Therapeutics during the third quarter valued at about $671,000. BNP Paribas Arbitrage SNC bought a new stake in Kymera Therapeutics during the 3rd quarter valued at approximately $1,650,000. Public Employees Retirement System of Ohio purchased a new position in Kymera Therapeutics in the 3rd quarter worth approximately $431,000. Twinbeech Capital LP bought a new position in Kymera Therapeutics in the 3rd quarter worth approximately $1,033,000. Finally, Martingale Asset Management L P purchased a new stake in Kymera Therapeutics during the 3rd quarter valued at approximately $210,000.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Kymera Therapeutics wasn’t on the list.
While Kymera Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Wells Fargo & Company Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $42.00